tiprankstipranks
Medexus Awaits FDA Decision on Treosulfan After Delay
Company Announcements

Medexus Awaits FDA Decision on Treosulfan After Delay

Story Highlights

Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.

Don't Miss Our Christmas Offers:

Medexus Pharmaceuticals has announced that the FDA has extended the review period for the New Drug Application (NDA) of treosulfan, a drug intended for use in stem cell transplantation for leukemia and myelodysplastic syndromes, by three months with a new target action date set for January 30, 2025. The extension is due to the FDA needing more time to review additional analyses but does not require new clinical data. The company remains optimistic and is preparing for a potential approval and commercial launch in the first half of 2025.

For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedexus Pharmaceuticals Secures Deal for Trecondyv in Canada
TipRanks Canadian Auto-Generated NewsdeskMedexus Pharmaceuticals Reports Strong Q2 2025 Results
TipRanks Canadian Auto-Generated NewsdeskMedexus Shareholders Show Strong Support at Annual Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App